ATE214100T1 - Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem - Google Patents

Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem

Info

Publication number
ATE214100T1
ATE214100T1 AT95902725T AT95902725T ATE214100T1 AT E214100 T1 ATE214100 T1 AT E214100T1 AT 95902725 T AT95902725 T AT 95902725T AT 95902725 T AT95902725 T AT 95902725T AT E214100 T1 ATE214100 T1 AT E214100T1
Authority
AT
Austria
Prior art keywords
bovine adenovirus
production
expression vector
recombinant proteins
vector system
Prior art date
Application number
AT95902725T
Other languages
English (en)
Inventor
Suresh K Mittal
Frank L Graham
Ludvik Prevec
Lorne A Babiuk
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE214100T1 publication Critical patent/ATE214100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95902725T 1993-12-09 1994-12-09 Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem ATE214100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/164,292 US5820868A (en) 1993-12-09 1993-12-09 Recombinant protein production in bovine adenovirus expression vector system
PCT/CA1994/000678 WO1995016048A2 (en) 1993-12-09 1994-12-09 Recombinant protein production in bovine adenovirus expression vector system

Publications (1)

Publication Number Publication Date
ATE214100T1 true ATE214100T1 (de) 2002-03-15

Family

ID=22593842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902725T ATE214100T1 (de) 1993-12-09 1994-12-09 Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem

Country Status (6)

Country Link
US (5) US5820868A (de)
EP (1) EP0736100B1 (de)
AT (1) ATE214100T1 (de)
AU (1) AU1189195A (de)
DE (1) DE69430071T2 (de)
WO (1) WO1995016048A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
US6319716B1 (en) 1997-06-23 2001-11-20 University Of Saskatchewan Bovine adenovirus type 3 genome and vector systems derived therefrom
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
WO2000026395A2 (en) * 1998-11-02 2000-05-11 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
US6303362B1 (en) * 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2365911A1 (en) * 1999-04-09 2000-10-19 Schering-Plough Ltd. Recombinant and mutant adenoviruses derived of bovine adenovirus type 1
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU6280600A (en) * 1999-08-06 2001-03-05 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Non-human adenoviral vector for gene transfer, its use and the production thereof
WO2001014416A2 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
EP1427816A4 (de) 2001-09-18 2004-12-01 Clontech Lab Inc Auf stellenspezifischer rekombinase beruhendes verfahren zur herstellung von adenovirusvektoren
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
EP1504016A4 (de) * 2002-05-08 2006-11-22 Intronn Inc Verwendung von spliceosom-vermitteltem rna-trans-splicing, um adenoviren eine zellselektive replikation zu verleihen
US7687615B2 (en) * 2002-07-19 2010-03-30 University Of Saskatchewan PAV regions for encapsidation and E1 transcriptional control
AU2003285009B2 (en) * 2002-10-23 2010-10-07 Virxsys Corporation Screening methods for identification of efficient pre-trans-splicing molecules
EP1631582A2 (de) * 2003-06-10 2006-03-08 University of Saskatchewan Chimäre adenoviruscapsidproteine
WO2004108939A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Bav packaging regions and e1 transcriptional control regions
CA2538025C (en) * 2003-10-02 2012-07-17 Crucell Holland B.V. Packaging cells for recombinant adenovirus
WO2005067506A2 (en) * 2004-01-06 2005-07-28 Cedars-Sinai Medical Center Method for monitoring and generating high capacity gutless adenoviral vector
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20060177933A1 (en) * 2004-01-23 2006-08-10 Madaiah Puttaraju Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
EP1773858B1 (de) 2004-05-27 2016-06-22 Janssen Biotech, Inc. Prostataspezifisches cynomolusantigen
AU2005329405A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
AU2005326784B2 (en) * 2004-10-08 2012-03-15 Virxsys Corporation Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
EP1863511A2 (de) * 2005-02-23 2007-12-12 UAB Research Foundation Alkyl-glykosid-verstärkte impfung
WO2006113214A2 (en) * 2005-04-11 2006-10-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Vaccine against pandemic strains of influenza viruses
SG11201503289XA (en) * 2012-11-15 2015-05-28 Univ Singapore Univariant extrinsic initiator control system for microbes and an in vitro assembly of large recombinant dna molecules from multiple components
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
CA3036310A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
TWI780070B (zh) 2016-09-20 2022-10-11 德商百靈佳殷格翰維美迪加股份有限公司 新穎之啟動子
US10525127B2 (en) * 2018-03-31 2020-01-07 Femtomab P14.7 protein and uses thereof as vaccine adjuvant

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB185573A (en) 1921-07-12 1922-09-14 Richard Saleck Apparatus for measuring off and cutting strings in bundles
US3962424A (en) * 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS62502662A (ja) * 1985-05-01 1987-10-15 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 外来性ｄｎａの高レベル増幅および発現
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
FR2642797B1 (fr) * 1989-01-10 1991-05-17 Secmair Dispositif d'asservissement de la pression d'appui au sol d'un rouleau equipant une tete de coupe, notamment de fauchage
FR2642767B1 (fr) 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
ATE140154T1 (de) * 1989-03-24 1996-07-15 Wistar Inst Rekombinanter cytomegalovirus-impfstoff
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2657880A1 (fr) * 1990-02-02 1991-08-09 Fondation Nale Transfusion San Production de proteines recombinantes a partir de cellules lymphoblastouides humaines et d'heteromyelomes.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU4857496A (en) 1995-01-17 1996-08-07 Environmental Projects, Inc. Method for purification of saline minerals
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
JP2001520511A (ja) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
US6319716B1 (en) 1997-06-23 2001-11-20 University Of Saskatchewan Bovine adenovirus type 3 genome and vector systems derived therefrom
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
JP2004504035A (ja) 2000-07-14 2004-02-12 ユニバーシティ　オブ　サスカチュワン イントロンを含むアデノウイルスベクター
US20030143200A1 (en) 2001-09-24 2003-07-31 Tikoo Suresh K. Porcine adenovirus E1 region
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions

Also Published As

Publication number Publication date
US6086890A (en) 2000-07-11
EP0736100B1 (de) 2002-03-06
US5820868A (en) 1998-10-13
US6001591A (en) 1999-12-14
DE69430071D1 (de) 2002-04-11
US20020192185A1 (en) 2002-12-19
AU1189195A (en) 1995-06-27
US7025967B2 (en) 2006-04-11
WO1995016048A3 (en) 1995-09-28
WO1995016048A2 (en) 1995-06-15
EP0736100A1 (de) 1996-10-09
US6379944B1 (en) 2002-04-30
DE69430071T2 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
ATE214100T1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
ES8306797A1 (es) Un metodo para producir un polipeptido.
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
AU3867789A (en) Recombinant mycobacterial expression vehicles and uses therefor
ATE80180T1 (de) Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels ''protein-engineering''.
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
EP0766569A4 (de) Aaw-hülltransporter für den molekularen transfer
EA199700244A1 (ru) Слитый белок, экспрессирующий вектор, рекомбинантный штамм, вакцинный препарат
ZA200201043B (en) Novel B7-4 molecules and uses thereof.
ES2177475T1 (es) Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
US11951120B2 (en) Modification of gene transcription and translation efficiency by 5′UTR sequence variation
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
DE69531387D1 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
HUT36860A (en) Process for preparing cdns clones determining polypeptides expressing cell growth factor activity influencing plural cell lines and/or mastocyte growth factor activity
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
ATE420182T1 (de) Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
Rassoulzadegan et al. Two polyoma virus gene functions involved in the expression of the transformed phenotype in FR 3T3 rat cells I. Localization of a transformation maintenance function in the proximal half of the large T coding region
EP1412374A4 (de) Neue pgc-1-isoformen und deren verwendungen
DE69941099D1 (de) Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria
ES2059431T3 (es) Mutantes de la creatinamidinohidrolasa estables.
EP0688224A4 (de) Ein mutiertes protein und verfahren und materialien zu seiner herstellung und verwendung
ES2120409T3 (es) Nuevos vectores de expresion y metodos para la produccion de proteinas intracelulares.
Tait et al. The production of proteins by bacterial plasmids containing eukaryotic DNA fragments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties